Astellas Pharma Aktie
WKN DE: A0YGQP / ISIN: US04623U1025
16.11.2023 02:08:23
|
Astellas Pharma To Buy Propella Therapeutics For About $175 Mln
(RTTNews) - Astellas Pharma Inc. (ALPMY, ALPMY) agreed to buy Propella Therapeutics Inc. for about US$175 million.
Propella is a privately held biopharmaceutical company that has leveraged a wholly owned proprietary platform that combines medicinal chemistry with lymphatic targeting to create new oncology drugs.
Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer. PRL-02 is currently in a Phase 1 clinical trial and is expected to enter Phase 2a clinical trials in 2024.
The transaction is expected to occur during Astellas' fiscal year 2023.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Astellas Pharma Inc Unsponsored American Deposit Receipt Repr 1-4 Shmehr Nachrichten
20.01.25 |
Erste Schätzungen: Astellas Pharma gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) | |
29.10.24 |
Ausblick: Astellas Pharma stellt Zahlen zum jüngsten Quartal vor (finanzen.net) | |
15.10.24 |
Erste Schätzungen: Astellas Pharma zieht Bilanz zum abgelaufenen Quartal (finanzen.net) |